Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Managing adverse events associated with TKIs in CML

Jorge Cortes • 4 Jun 2022
ASCO 2022
Chronic Myeloid Leukemia Leukemia

Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, discusses the management of adverse events associated with the use of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML), such as dose adjustments associated with pleural effusions or elevation of transaminases. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Jorge Cortes

Incorporating patient goals into frontline TKI selection in CML
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
Optimizing frontline therapy selection to prevent resistance in CML
1:58
Optimizing frontline therapy selection to prevent resistance in CML
Jorge Cortes • 10 Sep 2026
Managing patients with CML and additional genetic abnormalities
1:34
Managing patients with CML and additional genetic abnormalities
Jorge Cortes • 10 Sep 2026
Where does the treatment landscape for managing frontline CML currently stand?
1:44
Where does the treatment landscape for managing frontline CML currently stand?
Jorge Cortes • 10 Sep 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals